Your browser doesn't support javascript.
loading
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction.
Seferovic, Petar M; Polovina, Marija; Adlbrecht, Christopher; Belohlávek, Jan; Chioncel, Ovidiu; Goncalvesová, Eva; Milinkovic, Ivan; Grupper, Avishay; Halmosi, Róbert; Kamzola, Ginta; Koskinas, Konstantinos C; Lopatin, Yuri; Parkhomenko, Alexander; Põder, Pentti; Ristic, Arsen D; Sakalyte, Gintare; Trbusic, Matias; Tundybayeva, Meiramgul; Vrtovec, Bojan; Yotov, Yoto T; Milicic, Davor; Ponikowski, Piotr; Metra, Marco; Rosano, Giuseppe; Coats, Andrew J S.
Afiliação
  • Seferovic PM; Faculty of Medicine, Belgrade University, Belgrade, Serbia.
  • Polovina M; Serbian Academy of Sciences and Arts, Belgrade, Serbia.
  • Adlbrecht C; Faculty of Medicine, Belgrade University, Belgrade, Serbia.
  • Belohlávek J; Department of Cardiology, University Clinical Centre, Belgrade, Serbia.
  • Chioncel O; Imed19-privat, Private Clinical Research Center, Vienna, Austria.
  • Goncalvesová E; Second Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic.
  • Milinkovic I; University of Medicine Carol Davila, Bucharest, Romania.
  • Grupper A; Emergency Institute for Cardiovascular Diseases "Prof. C.C. Iliescu", Bucharest, Romania.
  • Halmosi R; Department of Cardiology, Faculty of Medicine Comenius University and National Cardiovascular Institute, Bratislava, Slovakia.
  • Kamzola G; Faculty of Medicine, Belgrade University, Belgrade, Serbia.
  • Koskinas KC; Department of Cardiology, University Clinical Centre, Belgrade, Serbia.
  • Lopatin Y; Cardiology Division, Sheba Medical Center and Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
  • Parkhomenko A; First Department of Medicine, University of Pecs, Medical School, Pecs, Hungary.
  • Põder P; Kamzola: Latvian Centre of Cardiology, Pauls Stradins Clinical University Hospital, Riga, Latvia.
  • Ristic AD; Department of Cardiology, Bern University Hospital, Bern, Switzerland.
  • Sakalyte G; Regional Cardiology Centre Volgograd, Volgograd State Medical University, Volgograd, Russian Federation.
  • Trbusic M; Emergency Cardiology Department, Institute of Cardiology, Kyiv, Ukraine.
  • Tundybayeva M; First Cardiology Department, North Estonia Medical Centre Foundation, Tallinn, Estonia.
  • Vrtovec B; Faculty of Medicine, Belgrade University, Belgrade, Serbia.
  • Yotov YT; Department of Cardiology, University Clinical Centre, Belgrade, Serbia.
  • Milicic D; Department of Cardiology, Medical Academy, Faculty of Medicine Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Ponikowski P; School of Medicine, University of Zagreb, Zagreb, Croatia.
  • Metra M; Department of Cardiology, Kazakh National Medical University, Almaty, Kazakhstan.
  • Rosano G; Department of Cardiology, UMC, Ljubljana, Slovenia.
  • Coats AJS; First Department of Internal Medicine, Medical University of Varna, Varna, Bulgaria.
Eur J Heart Fail ; 23(12): 1999-2007, 2021 12.
Article em En | MEDLINE | ID: mdl-34755422
Guideline-directed medical therapy (GDMT) has the potential to reduce the risks of mortality and hospitalisation in patients with heart failure (HF) with reduced ejection fraction (HFrEF). However, real-world data indicate that many patients with HFrEF do not receive optimised GDMT, which involves several different medications, many of which require up-titration to target doses. There are many challenges to implementing GDMT, the most important being patient-related factors (comorbidities, advanced age, frailty, cognitive impairment, poor adherence, low socioeconomic status), treatment-related factors (intolerance, side-effects) and healthcare-related factors that influence availability and accessibility of HF care. Accordingly, international disparities in resources for HF management and limited public reimbursement of GDMT, coupled with clinical inertia for treatment intensification combine to hinder efforts to provide GDMT. In this review paper, authors aim to provide solutions based on available evidence, practical experience, and expert consensus on how to utilise evolving strategies, novel medications, and patient profiling to allow the more comprehensive uptake of GDMT. Authors discuss professional education, motivation, and training, as well as patient empowerment for self-care as important tools to overcome clinical inertia and boost GDMT implementation. We provide evidence on how multidisciplinary care and institutional accreditation can be successfully used to increase prescription rates and adherence to GDMT. We consider the role of modern technologies in advancing professional and patient education and facilitating patient-provider communication. Finally, authors emphasise the role of novel drugs (especially sodium-glucose co-transporter 2 inhibitors), and a tailored approach to drug management as evolving strategies for the more successful implementation of GDMT.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Eur J Heart Fail Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Insuficiência Cardíaca Tipo de estudo: Guideline Limite: Humans Idioma: En Revista: Eur J Heart Fail Ano de publicação: 2021 Tipo de documento: Article